IL309453A - Methods for quantitating individual antibodies from a mixture - Google Patents

Methods for quantitating individual antibodies from a mixture

Info

Publication number
IL309453A
IL309453A IL309453A IL30945323A IL309453A IL 309453 A IL309453 A IL 309453A IL 309453 A IL309453 A IL 309453A IL 30945323 A IL30945323 A IL 30945323A IL 309453 A IL309453 A IL 309453A
Authority
IL
Israel
Prior art keywords
antibody
antibodies
protein
hic
quantitating
Prior art date
Application number
IL309453A
Other languages
English (en)
Hebrew (he)
Inventor
Dingjiang Liu
Lin Luo
Long Xu
Original Assignee
Regeneron Pharma
Dingjiang Liu
Lin Luo
Long Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Dingjiang Liu, Lin Luo, Long Xu filed Critical Regeneron Pharma
Publication of IL309453A publication Critical patent/IL309453A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/30—Partition chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
IL309453A 2016-08-16 2017-08-08 Methods for quantitating individual antibodies from a mixture IL309453A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375887P 2016-08-16 2016-08-16
PCT/US2017/045855 WO2018034885A1 (en) 2016-08-16 2017-08-08 Methods for quantitating individual antibodies from a mixture

Publications (1)

Publication Number Publication Date
IL309453A true IL309453A (en) 2024-02-01

Family

ID=59702834

Family Applications (2)

Application Number Title Priority Date Filing Date
IL309453A IL309453A (en) 2016-08-16 2017-08-08 Methods for quantitating individual antibodies from a mixture
IL264631A IL264631B2 (en) 2016-08-16 2017-08-08 A method for quantifying individual antibodies from a mixture

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL264631A IL264631B2 (en) 2016-08-16 2017-08-08 A method for quantifying individual antibodies from a mixture

Country Status (15)

Country Link
US (5) US11020686B2 (OSRAM)
EP (2) EP3500297A1 (OSRAM)
JP (3) JP2019529350A (OSRAM)
KR (3) KR20230041834A (OSRAM)
CN (2) CN109641050A (OSRAM)
AU (2) AU2017312785B2 (OSRAM)
BR (1) BR112019000872A2 (OSRAM)
CA (1) CA3031742A1 (OSRAM)
EA (1) EA201990317A1 (OSRAM)
IL (2) IL309453A (OSRAM)
MX (1) MX2019000935A (OSRAM)
MY (2) MY196321A (OSRAM)
SG (1) SG11201900201YA (OSRAM)
WO (1) WO2018034885A1 (OSRAM)
ZA (1) ZA201900350B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR20190127655A (ko) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. 음향학에 의한 친화성 세포 추출
EP3725092A4 (en) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER
WO2019243626A1 (en) * 2018-06-22 2019-12-26 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
EP3886921A4 (en) * 2018-11-30 2022-11-23 Actinium Pharmaceuticals, Inc. ACTINIUM 225 AND ACTINIUM 227 CONJUGATED ANTIBODIES, COMPOSITIONS AND METHODS RELATED
ES3027676T3 (en) * 2019-01-16 2025-06-16 Regeneron Pharma Method and system of identifying and quantifying antibody fragmentation
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
AU2021254279A1 (en) 2020-04-09 2022-11-10 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
CN113588582B (zh) * 2020-04-30 2024-05-14 上海药明生物技术有限公司 蛋白质样品浓度测定方式选择法及测定方法
EP4161960A1 (en) 2020-06-03 2023-04-12 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
CN114577885B (zh) * 2020-12-01 2024-03-29 齐鲁制药有限公司 一种检测重组组合抗体含量比例、电荷异质性和/或等电点的方法
WO2023287875A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2025049384A1 (en) * 2023-08-31 2025-03-06 Amgen Inc. Methods for analyzing antibody co-formulations

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801726A (en) 1986-04-15 1989-01-31 Northeastern University Repetitive hit-and-run immunoassay and stable support-analyte conjugates; applied to T-2 toxin
US5190864A (en) 1986-04-15 1993-03-02 Northeastern University Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material
US4937188A (en) 1986-04-15 1990-06-26 Northeastern University Enzyme activity amplification method for increasing assay sensitivity
US5412083A (en) 1992-04-16 1995-05-02 Northeastern University Carbohydrate heterobifunctional cross-linking reagent
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AU4986596A (en) 1995-02-16 1996-09-04 Massachusetts Health Research Institute, Inc. Purified tetanus toxoid and toxin
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
EP0964057B1 (en) 1998-05-11 2004-12-22 Tosoh Corporation Method for separating nucleic acids by means of liquid chromatography
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
US7101982B2 (en) 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
WO2004020971A2 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
WO2004024284A2 (en) 2002-09-13 2004-03-25 Biogen Idec Inc. Method of purifying polypeptides by simulated moving bed chromatography
SE0300612D0 (sv) * 2003-03-05 2003-03-05 Amersham Biosciences Ab A method of preparing ligands for hydrophobic interaction chromatography
US20060257972A1 (en) 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
AU2004252171B2 (en) 2003-06-27 2011-04-21 Biogen Ma Inc. Modified binding molecules comprising connecting peptides
EP1687328B1 (en) 2003-10-24 2010-03-31 Amgen, Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
CA2552639C (en) 2004-02-27 2012-05-01 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
WO2006020622A1 (en) 2004-08-09 2006-02-23 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
US7795405B2 (en) 2004-08-09 2010-09-14 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
JP4831436B2 (ja) 2004-10-21 2011-12-07 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ クロマトグラフィーリガンド
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
US20080299671A1 (en) 2005-12-02 2008-12-04 Ge Healthcare Bio-Sciences Ab Hydrophobic Interaction Chromatography
JP2009531371A (ja) 2006-03-28 2009-09-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
PT2944306T (pt) 2006-06-16 2021-02-15 Regeneron Pharma Formulações antagonistas de vegf adequadas para administração intravitreal
WO2008028974A1 (en) 2006-09-08 2008-03-13 Novo Nordisk A/S Methods of optimizing chromatographic separation of polypeptides
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
EP2097756B1 (en) * 2006-12-21 2011-10-19 Novartis AG Antibody quantitation
US20080299545A1 (en) 2007-03-06 2008-12-04 Shuyuan Zhang Chromatographic methods for assessing adenovirus purity
AU2008251608B2 (en) * 2007-05-08 2014-03-27 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
WO2009094203A2 (en) 2008-01-25 2009-07-30 Biogen Idec Ma Inc. Automated system and method for monitoring chromatography column performance, and applications thereof
WO2010019814A1 (en) 2008-08-15 2010-02-18 Biogen Idec Ma Inc. Methods for evaluating chromatography column performance
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
CN105111309A (zh) 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
WO2010129469A1 (en) 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
JP5956331B2 (ja) 2009-06-16 2016-07-27 ジェンザイム・コーポレーション 組換えａａｖベクターの改良された精製方法
US9289699B2 (en) * 2009-07-30 2016-03-22 Hoffmann-La Roche Inc. Moveable chromatography column separator
WO2011028961A2 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
MX341136B (es) 2009-10-20 2016-08-09 Abbvie Inc Aislamiento y purificacion de los anticuerpos anti-il-13 al usar la cromatografia de afinidad con proteina a.
US8246833B2 (en) 2009-12-17 2012-08-21 Ge Healthcare Bio-Sciences Ab Chromatography column and maintenance method
KR20120118065A (ko) 2010-02-12 2012-10-25 디에스엠 아이피 어셋츠 비.브이. 단일 단위체 항체 정제
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
JP5919606B2 (ja) 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
EP2500073A1 (en) * 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
DK2768857T3 (da) 2011-10-19 2020-02-03 Novimmune Sa Fremgangsmåder til oprensning af antistoffer
EP2773439A4 (en) 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
WO2013074557A1 (en) 2011-11-14 2013-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
CN104066748A (zh) 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
BR112014011900A2 (pt) 2011-12-15 2017-05-16 Hanwha Chemical Corp um método de purificação de anticorpo
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2879691B1 (en) 2012-08-06 2019-03-27 Biogen MA Inc. Methods for inactivating enveloped viruses
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CA2895198A1 (en) 2012-12-20 2014-06-26 Medimmune, Llc Liquid antibody formulation with improved aggregation properties
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
IL274646B (en) 2013-03-08 2022-09-01 Genzyme Corp Integrated continuous production of medicinal substances from medical protein
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014142591A1 (ko) * 2013-03-13 2014-09-18 (주) 아이벤트러스 소수성 상호작용 부위내에 전기적 상호작용이 도입된 단백질 및 이의 제조방법
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2926384A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
TWI670279B (zh) 2013-03-15 2019-09-01 美商艾爾德生物製藥股份有限公司 抗體純化及純度監測
WO2014152199A1 (en) * 2013-03-15 2014-09-25 Abbvie Inc. Antibody drug conjugate (adc) purification
US9994609B2 (en) 2013-03-15 2018-06-12 Biogen Ma Inc. Hydrophobic interaction protein chromatography under no-salt conditions
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR101569783B1 (ko) 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
US9150938B2 (en) 2013-06-12 2015-10-06 Orochem Technologies, Inc. Tagatose production from deproteinized whey and purification by continuous chromatography
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
RU2016112549A (ru) 2013-09-05 2017-10-10 Дженентек, Инк. Способ для повторного использования хроматографии
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR20160055269A (ko) * 2013-09-20 2016-05-17 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
JP2016538267A (ja) 2013-10-25 2016-12-08 メディミューン，エルエルシー 抗体精製
US10115576B2 (en) 2013-12-12 2018-10-30 Waters Technologies Corporation Method and an apparatus for analyzing a complex sample
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
FR3025515B1 (fr) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
JP2016088937A (ja) * 2014-10-31 2016-05-23 オーストリッチファーマ株式会社 エボラウイルスに対する抗体および抗体の製造方法
AU2015355150A1 (en) 2014-12-02 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods for treating dry eye disease by administering an IL-6R antagonist
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
BR112018012801B1 (pt) 2015-12-22 2024-03-12 Regeneron Pharmaceuticals, Inc Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica
KR20180087401A (ko) 2015-12-22 2018-08-01 리제너론 파아마슈티컬스, 인크. 급성 림프아구성 백혈병을 치료하기 위한 이중특이성 항-cd20/항-cd3 항체
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
GB201602938D0 (en) 2016-02-19 2016-04-06 Ucb Biopharma Sprl Protein purification
BR112018075667B1 (pt) 2016-06-14 2024-02-20 Biogen Ma, Inc Métodos para separar um oligonucleotídeo alvo de uma mistura contendo o oligonucleotídeo alvo e uma impureza relacionada com o produto
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US11697670B2 (en) 2017-08-22 2023-07-11 Biogen Ma Inc. Methods for purifying antibodies having reduced high molecular weight aggregates
US12325875B2 (en) 2018-03-16 2025-06-10 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
WO2019178495A1 (en) 2018-03-16 2019-09-19 Biogen Ma Inc. Methods for purifying recombinant adeno-associated viruses
WO2019191416A1 (en) 2018-03-29 2019-10-03 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies
CN112566930A (zh) 2018-06-19 2021-03-26 百时美施贵宝公司 使用色谱纯化蛋白质的方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US20220267369A1 (en) 2018-07-25 2022-08-25 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
CN112805300A (zh) 2018-08-15 2021-05-14 百时美施贵宝公司 下游色谱法中依据再氧化的蛋白质片段化控制策略
CN113301922A (zh) 2018-11-05 2021-08-24 百时美施贵宝公司 用于纯化聚乙二醇化蛋白的方法
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
CN113646630B (zh) 2019-03-29 2024-05-07 百时美施贵宝公司 测量色谱树脂的疏水性的方法
CN114173827B (zh) 2019-06-28 2025-01-28 武田药品工业株式会社 腺相关病毒纯化方法

Also Published As

Publication number Publication date
KR20220025943A (ko) 2022-03-03
EP4183414A1 (en) 2023-05-24
AU2025200089A1 (en) 2025-01-23
US11020686B2 (en) 2021-06-01
US11369896B2 (en) 2022-06-28
WO2018034885A1 (en) 2018-02-22
CN119119244A (zh) 2024-12-13
US20230415073A1 (en) 2023-12-28
AU2017312785A1 (en) 2019-01-24
SG11201900201YA (en) 2019-02-27
MY196321A (en) 2023-03-24
EA201990317A1 (ru) 2019-07-31
EP3500297A1 (en) 2019-06-26
ZA201900350B (en) 2025-05-28
MY198401A (en) 2023-08-28
KR102511050B1 (ko) 2023-03-17
CA3031742A1 (en) 2018-02-22
IL264631A (en) 2019-02-28
US20210268404A1 (en) 2021-09-02
KR102369014B1 (ko) 2022-03-02
MX2019000935A (es) 2019-07-04
US11571636B2 (en) 2023-02-07
IL264631B1 (en) 2024-01-01
IL264631B2 (en) 2024-05-01
US11850535B2 (en) 2023-12-26
JP2022159388A (ja) 2022-10-17
BR112019000872A2 (pt) 2019-04-30
US20210031123A1 (en) 2021-02-04
AU2017312785B2 (en) 2024-10-10
JP2019529350A (ja) 2019-10-17
US20230119592A1 (en) 2023-04-20
CN109641050A (zh) 2019-04-16
US20190184312A1 (en) 2019-06-20
KR20230041834A (ko) 2023-03-24
KR20190039144A (ko) 2019-04-10
JP2024173983A (ja) 2024-12-13

Similar Documents

Publication Publication Date Title
IL309453A (en) Methods for quantitating individual antibodies from a mixture
JP2019529350A5 (OSRAM)
WO2017193032A3 (en) Bispecific binding proteins and uses thereof
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2020536488A5 (OSRAM)
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
FI2897981T3 (fi) Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä
JP2018536393A5 (OSRAM)
BR112014030797A2 (pt) epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
WO2015038884A3 (en) Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
Finney et al. Predicting antidisease immunity using proteome arrays and sera from children naturally exposed to malaria
FI3390442T3 (fi) Anti-C5-vasta-aineita ja käyttömenetelmiä
NZ603619A (en) Antibodies that bind to il-12 and methods of purifying the same
HK1248721A1 (zh) 抗体分子及其用途
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
BR112021017046A2 (pt) Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos
BR112021020357A2 (pt) Anticorpos anti-cd3 de alta afinidade e métodos para sua geração e uso
JP2017510627A5 (OSRAM)
BR112018009882A2 (pt) gradientes de ph-sal opostos para separações melhoradas de proteína
CN109661577A (zh) 使用浓度相关的自相互作用纳米粒子光谱法确定蛋白质自缔合的可能性的测定
NZ754606A (en) Anti-il-5 antibodies
MX2022003432A (es) Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada.
WO2005114218B1 (en) Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule